SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-17-020453
Filing Date
2017-10-31
Accepted
2017-10-31 08:01:07
Documents
46
Period of Report
2017-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q ntla-10q_20170930.htm 10-Q 1320826
2 EX-31.1 ntla-ex311_7.htm EX-31.1 8313
3 EX-31.2 ntla-ex312_6.htm EX-31.2 8286
4 EX-32.1 ntla-ex321_8.htm EX-32.1 6200
5 GRAPHIC g2017103103232061412554.jpg GRAPHIC 30532
  Complete submission text file 0001564590-17-020453.txt   3747428

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT ntla-20170930.xml EX-101.INS 670849
7 XBRL TAXONOMY EXTENSION SCHEMA ntla-20170930.xsd EX-101.SCH 28215
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ntla-20170930_cal.xml EX-101.CAL 25242
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ntla-20170930_def.xml EX-101.DEF 61491
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20170930_lab.xml EX-101.LAB 219024
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20170930_pre.xml EX-101.PRE 155052
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37766 | Film No.: 171164066
SIC: 2835 In Vitro & In Vivo Diagnostic Substances